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Abstract
High-dimensional data can be useful for causal inference by providing many con-
founders that may bolster the plausibility of the ignorability assumption. Propensity
score methods are powerful tools for causal inference, are popular in health care re-
search, and are particularly useful for high-dimensional data. Recent interest has sur-
rounded a Bayesian formulation of these methods in order to flexibly estimate propen-
sity scores and summarize posterior quantities while incorporating variance from the
(potentially high-dimensional) treatment model. We discuss methods for Bayesian
propensity score analysis of binary treatments, focusing on modern methods for high-
dimensional Bayesian regression and the propagation of uncertainty from the treatment
regression. We introduce a novel and simple estimator for the average treatment ef-
fect that capitalizes on conjugancy of the beta and binomial distributions. Through
simulations, we show the utility of horseshoe priors and Bayesian additive regression
trees paired with our new estimator, while demonstrating the importance of including
variance from the treatment and outcome models. Cardiac stent data with almost 500
confounders and 9000 patients illustrate approaches and compare among existing fre-
quentist alternatives.
Keywords: Bayesian methods; propensity score weighting; regularization; Bayesian
additive regression trees; coronary stent.
1 Introduction
Comparative effectiveness research examines which health care interventions work best
for which patients. These questions are typically causal in nature and frequently informed
by randomized clinical trials (RCTs). When experimental evidence is unavailable, causal
inferences may be drawn from observational data such as information found in health care
databases. Propensity score approaches that condition on treatment assignment probabil-
ities are often used to adjust for confounding and attain unbiased causal effects provided
key assumptions are met. They have a central role in applied causal inference for inferring
effectiveness of interventions in usual care settings or in regulatory settings for clearance
of medical devices [12]. One key feature to the validity of findings is that propensity score
approaches build treatment models without reference to outcome information in analogy to
randomized trials, an outcome free design. This feature is vital for high-dimensional causal
inference problems where many potential confounders are available [26][2][29].
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Recent work has attempted to bring propensity scores into the domain of Bayesian
inference. It is difficult to reconcile the Bayesian paradigm, in which all parameters of in-
terest are jointly estimated, with propensity scores, in which outcome and treatment models
are explicitly separated. Nevertheless, Bayesian methods offer their own suite of tools for
model building, provide intuitive ways to present posterior summaries of parameters, and
propagate uncertainty from all stages of model fitting [22][18][35][28][10]. For these reasons,
Bayesian propensity scores remain an appealing concept and an exciting area for method-
ological advancement. The propagation of uncertainty is a particularly important feature
for high-dimensional causal inference, as the treatment model becomes the main source of
variance.
Our work is motivated by a comparison of the effectiveness of two treatment alter-
natives for percutaneous coronary intervention (PCI) in a cohort of patients treated in
Massachusetts non-federal hospitals. These interventions are standard care for clearing
blockages in the blood vessels supplying the heart and frequently include the installation of
a coronary stent to keep the treated artery clear and supported. We focus on two classes
of coronary stents available in the U.S. market: bare-metal (BMS) which were first ap-
proved in the U.S. in the 1990s and drug-eluting (DES) approved in the U.S. in 2003.
Many randomized clinical trials, meta-analyses, and observational studies have compared
the effectiveness of DESs and BMSs for patients with a range of conditions [32][20][4]. Our
main data source is the Mass-DAC clinical registry, a state mandated database harvesting
clinical information for all PCIs performed in adults (age ≥ 18 years) in all non-federal Mas-
sachusetts’ hospitals annually. We sought to estimate the causal effect of DES compared to
BMS on repeat target-vessel revascularization (TVR) and on all-cause mortality within 1
year of the initial implant. Our data, examining stents implanted in 2011, includes about
9,000 patients undergoing coronary stenting and approximately 500 confounders. A small
subset of these confounders and outcomes appears in table 1. Generally, BMS patients are
sicker and older than DES patients, confounding a naive estimate of causal effect based on
raw outcomes.
Table 1: Prevalence or mean (SD) of selected confounders and outcomes in Mass-DAC
data. TVR = target vessel revascularization; STEMI = ST-elevated myocardial infarction;
LVSD = left ventricular systolic dysfunction.
Stent Type
Characteristic Overall Bare Metal Drug Eluting
Outcomes
1-Year Mortality, % 5.7 10.2 3.3
1-Year TVR, % 7.4 9.0 6.5
Confounders
Mean Age (SD), yrs 64.7 (12.5) 66.4 (11.7) 63.7 (13.5)
STEMI, % 24.4 35.7 18.2
Cardiomyopathy or LVSD, % 9.4 11.1 8.4
Emergent Status, % 26.7 38.3 20.3
Cardiogenic Shock, % 1.8 3.8 0.8
We propose a new method of Bayesian propensity score analysis for causal inference,
with emphasis on using high-dimensional data to meet the ignorability assumption - the
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assumption that treatment assignment does not depend on the potential outcomes. Our
method estimates a difference in outcome proportions in a weighted pseudo-population,
sharing links to frequentist inverse probability weighting (IPW) as well as the weighted
likelihood approach of [28]. By focusing on a Bayesian framework, we allow for intuitive and
flexible approaches to model building with many variables while propagating uncertainty in
the treatment model. We do not offer new theory on Bayesian propensity scores, referring
the interested reader to the extensive discussion in [28], and its accompanying critiques.
We assess our approach on the basis of finite sample frequentist characteristics such as
consistency, efficiency, and coverage through simulation studies.
We next briefly review the goals and assumptions of causal inference in section 2. Sec-
tion 3 provides background on propensity scores as a causal inference tool, introduces
Bayesian methods for regression with high-dimensional data, and discusses recent work in
developing a Bayesian framework for propensity scores. In section 4 we provide technical
details and propose a two-step propensity score weighting procedure using Bayesian compu-
tation. Finite sample performance obtained through a simulation study of our methods and
competing existing approaches is described in section 5. We return to the coronary stent
problem in section 6. Throughout we assume a binary treatment, referring to one arm as
treatment and the other arm generically as control. We label the “treatment model” as the
model characterizing the relationship between confounders and treatment, and the “out-
come model” as the model characterizing the relationship between treatment and outcome,
adjusting for confounders.
2 Assumptions for Causal Inference
We make three assumptions necessary for causal inference: positivity, stable unit treat-
ment value assignment (SUTVA), and ignorability. SUTVA encodes the assumptions that
observations do not interfere with one another and that the nature of treatment does not
vary across individuals. Positivity refers to the assumption that each subject has a chance
for assignment to either treatment group. It is difficult to test for positivity violations
in high-dimensions, as each subject is typically uniquely defined by some combination of
their covariates. We do assume positivity is met in our data and refer the reader to our
references for more information [23]. Our focus is on meeting the ignorability assumption
by exploiting high-dimensional data.
2.1 Ignorability
For a subject i, let Xi denote binary treatment, Y1i and Y0i potential outcomes under
treatment and control respectively, and Ci a vector of pre-treatment confounders. We are
interested in the treatment effect, E(Y0i) − E(Y1i). However we can never observe both
potential outcomes for a subjects. We can use observational data to estimate the treatment
effect if we are willing to assume that conditional on observed pre-treatment confounders,
treatment is independent of potential outcomes across the population [25]:
(Y0i, Y1i) ⊥ Xi|Ci.
Coupled with positivity, ignorability permits estimation of the average treatment effect
(ATE) defined here as the difference in marginal event rates under each treatment across
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the population:
∆ = EC[E(Y |X = 1,C)− E(Y |X = 0,C)].
If an important confounder is excluded from C, then the ignorability assumption is not
met and our estimate of ∆ will be biased. Thus in the observational setting, inclusion of
important confounders is essential to generating unbiased causal estimates.
3 Causal Inference and Bayesian Methods
3.1 Propensity Scores
For binary treatment the propensity score for subject i is defined as pi(Ci) = P(Xi =
1|Ci), the probability of receiving treatment given pre-treatment confounders. In their
seminal paper, [25] define the vector pi(C) = [pi(C1)...pi(Cn)] as a “balancing score”
and show that conditioning on it is sufficient to estimate unbiased causal effects, i.e.
(Y0, Y1) ⊥ X|pi(C). This fact is particularly useful in the high-dimensional setting be-
cause we only need to condition on the one-dimensional propensity score vector, pi(C),
rather than the entire matrix of confounders, C [25]. However, in the absence of random-
ization, the propensity scores must still be estimated from a regression of confounders on
treatment and a first step involves reducing the dimension of the confounders via variable
selection or by some method of regularization. Focusing on the treatment model only, an
outcome free design, is preferable over estimates based on outcome regression adjustment
because it reduces the risk of selective inference [26]. The user can design a good propensity
score model by assessing balance or overlap among confounders between treatment groups
and tweaking the propensity score model if necessary [2]. Because this approach reduces
investigator bias and shares important connections to randomized trials, propensity score
methods are recommended for use in observational studies by important regulators and
decision-makers [12].
3.2 Bayesian Propensity Scores
Several researchers have justified and implemented propensity scores in a fully Bayesian
framework by jointly modeling the outcome and treatment assignment mechanism [22][18][35].
In addition to adhering to the likelihood principle, an advantage of these approaches is that
instrumental variables can be screened out by the use of carefully constructed priors that
select variables associated with both treatment and outcome [35]. Nonetheless, strong
critiques have been raised involving three key aspects of fully Bayesian propensity score
methods. First, when the outcome model parameters are a-priori independent of the treat-
ment model, the propensity scores play no role in Bayesian inference. Second, if a-priori
treatment and outcome parameters are dependent then joint modeling of outcome and
treatment change the treatment balancing property of the propensity score. Finally, joint
modeling can be very sensitive to model misspecification, leading to poor calibration and
coverage [34][35][28][10].
We instead pursue a method along the lines of [18] and [28], who developed Bayesian
computational approaches by estimating the treatment and outcome models in two stages.
Due largely to the first criticism above, such a method is not widely accepted as formally
Bayesian [28]. Our treatment and outcome models are separately Bayesian, but the way
they are integrated is not. Thus our estimator must ultimately be assessed in terms of
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frequentist characteristics like coverage and consistency. Furthermore, because we main-
tain outcome free design, there is inherently no way to automatically screen instrumental
variables and, as in a typical propensity score analysis, we rely on background knowledge
to exclude instruments [2]. From a pragmatic viewpoint, we maintain the outcome free
design feature while allowing the use of Bayesian modeling strategies (Bayesian algorithms,
priors, posterior sampling, etc) for the propensity score model. Additionally, we propagate
uncertainty from both the propensity score and outcome model which improves frequentist
properties of causal estimators in high-dimensions [35]. As a further advantage, we generate
the full posterior density for the causal parameter of interest, allowing us to present results
more flexibly than we could relying on point estimates [10].
4 Proposed Approaches
We propose new approaches for both the treatment regression and outcome model of
a two-step Bayesian propensity score analysis. For the treatment regression, we estimate
Bayesian logistic models regularized by weakly informative or sparsity inducing priors, as
well as fully non-parametric Bayesian additive regression trees. For the outcome model, we
sample from separate beta posterior distributions whose arguments are based on a weighted
number of counts observed in the samples.
4.1 Regularization
Regularization is a popular technique in high-dimensional data analysis. Suppose we
wish to estimate a logistic regression model to predict a binary treatment X from con-
founders C with coefficients β = (β0, β1, ...βp):
Xi ∼ Bernoulli
{
logit−1(β0 +
p∑
j=1
βjCij)
}
. (1)
If p, the dimension of C, is large, the parameter vector β becomes highly variable and
the model tends to “over-fit” the data. Regularization trades a bit of bias for a relatively
large efficiency gain when estimating β. This controls overfitting and can reduce the mean
squared error of estimates. From a Bayesian perspective, regularization amounts to placing
informative prior distributions on parameters, often centered at zero. Commonly used reg-
ularizing distributions include normal, double-exponential (Bayesian lasso), and Student-t
distributions [13]. Choosing to exclude variable j based on subject matter knowledge is
equivalent to prior certainty that βj = 0.
Specification of priors can be very intuitive. For example, in a logistic regression we
might assume with 95% prior certainty that a binary confounder will not have a log-odds
effect greater than 5 in magnitude, which is quite large in our motivating example. A
zero-centered Student-t distribution with 3 degrees of freedom and scale 2.5 accomplishes
this, while heavy tails accommodate larger effect sizes if the data warrant. These are
called “weakly informative priors” [13]. With more complex prior specifications some inter-
pretability may be sacrificed for improved performance in high-dimensional settings. Ideal
regularization priors separate confounders from noisy variables, aggressively shrinking co-
variates towards zero to reduce variance while allowing the coefficients of true confounders
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to remain relatively unbiased. The horseshoe prior is a Bayesian regularization tool de-
signed for this purpose [6]. It has both a very high density near zero and fat tails that do
not over-shrink true signals. The horseshoe prior can be expressed as a scale mixture of
normal distributions:
βj ∼ N (0, λ2jτ2) where λj ∼ Cauchy+(0, 1) and τ ∼ Cauchy+(0, 1).
The parameter τ acts as a global scale parameter and controls the overall degree of shrink-
age; λj acts as a local scale parameter for each coefficient, allowing confounder coefficients
to be quite large while shrinking noisy coefficients towards zero. Weakly informative half-
Cauchy priors on λj and τ imply a fully Bayesian specification [13]. With default specifica-
tions, horseshoe priors outperform the cross-validated lasso in sparse prediction problems
and provide fully Bayesian inference [6].
Regularization in causal inference has garnered much attention, most of which is pred-
icated on outcome modeling. For a thorough review of recent developments in high-
dimensional causal inference see [16]. Recent highlights in the frequentist literature include
[14] that proposed lasso regularization for causal inference based on outcome regression, and
[11] that developed theory for doubly-robust estimation using the lasso. On the Bayesian
side, [33] proposed an algorithm using discrete priors with linked treatment and outcome
parameters to select variables likely to be confounders. Hahn et al [16] used horseshoe pri-
ors with a carefully chosen parameterization to estimate a treatment effect in a regularized
Bayesian outcome regression and [35] proposed a joint Bayesian propensity score approach
with discrete regularizing priors.
The downside to regularizing priors paired with logistic regression is that the user must
pre-specify the correct model form including interactions and non-linearities. This can be
particularly challenging when many potential confounders are available.
4.2 Bayesian Additive Regression Trees (BART)
BART is a nonparametric modeling technique that translates decision tree-based en-
semble methods, such as random forests, to a Bayesian framework. Such approaches are
especially desirable when the form of the model is unknown. [9] provide a thorough in-
troduction to the method. Broadly speaking, BART is a sum-of-trees model where prior
distributions are placed over the parameters including tree depth, splitting variables, split-
ting values, and terminal node (leaf) estimates. As in linear models, the priors allow for
regularization, while the Bayesian framework allows for posterior averaging and inference
using MCMC. However, like other tree-based methods, BART has a number of advantages
over linear models in that it automatically attempts to account for non-linearities and in-
teractions between variables. For binary dependent variables, BART is simply modified by
probit transforming the outputs such that they are on the probability scale [9]. Through
simulations and applications, [9] showed BART to be highly competitive against advanced
machine learning methods in prediction problems. [17] further demonstrated the efficacy
of BART when used as an outcome model for causal inference. Though Hill’s paper dealt
with relatively few variables, [9] showed that BART scales quite well to high-dimension
regression problems.
A sum-of-trees modeling approach to estimation of propensity scores resembles the
generalized boosted modeling (GBM) approach used by [21] in their application of boost-
ing to propensity score weighting. Like GBM, BART is data adaptive and works well in
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high-dimensional settings with little user input, but it also provides posterior inference
via MCMC [17]. For these reasons, BART is an appealing Bayesian option for estimating
a propensity score model. Further details of the algorithm and our implementation are
included in the supplementary appendix.
4.3 Propensity Score Weighting and Competitors
When used for a treatment regression, the fitted values from regularized Bayesian logistic
models and BART are samples from the propensity score distribution. Weighting is a
typical way of using propensity scores to get unbiased ATE estimates. Propensity score
weighting creates a pseudo-population of subjects from the original sample in which the
treatment effect is unconfounded by covariate imbalances between treatment groups. A
weighted estimator is given by:
∆IPW =
( n∑
i=1
Xi
pii
)−1 n∑
i=1
XiYi
pii
−
( n∑
i=1
1−Xi
1− pii
)−1 n∑
i=1
(1−Xi)Yi
1− pii (2)
where for brevity pii = pi(Ci).
Theoretical results and simulations studies show weighting to be superior to match-
ing or regression adjustment in some settings, though matching can sometimes be more
stable and intuitive in practice [1][19]. Weighting is also relatively interpretable and easy
to use, garnering an increasingly large user base among health care researchers [2]. For
these reasons and to avoid explicit modeling of the outcome regression, we develop below a
weighted estimator with close connections to equation (2). Augmented inverse probability
weighting (AIPW) comprise a doubly-robust and sometimes more efficient modification to
equation (2) [24]. Recent work has created Bayesian techniques for doubly-robust estima-
tion: [27] discuss theoretical connections and hurdles to Bayesian doubly-robust estimation,
[10] present an approximately Bayesian method based on the Bayesian bootstrap, and [7]
describe an algorithm for model-averaged doubly-robust estimates. Targeted maximum
likelihood is another doubly-robust alternative, though one that has been researched solely
in a frequentist framework [31].
In terms of inference, multiple proposals exist to derive the variance of equation (2),
including sample variances and the empirical sandwich method [19], as well as the non-
parametric bootstrap. Advantages of the bootstrap are that it works with arbitrary propen-
sity score models and can account for the uncertainty associated with the weights. Sim-
ulation studies have shown that bootstrapping propensity score weighting is competitive
with the sandwich variance and can outperform it in some settings [28][3]. Bootstrapping
provides approximate Bayesian posteriors with non-informative priors and, by refitting the
treatment regression on bootstrapped data, propagates uncertainty from estimation of the
propensity scores [3]. In this way, bootstrapping serves as a bridge between typical propen-
sity score estimators and methods that use more formal Bayesian models for propensity
scores [28][10].
4.4 Bayesian Propensity Score Weighting
The estimator in (2) generates a weighted pseudo-population by allowing every subject
to represent wi =
Xi
pii
+ 1−Xi1−pii subjects. Intuitively we are taking a difference in means
where treated subjects who “look like” untreated subjects (and vice versa) receive more
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weight, leading to an unconfounded point estimate of the causal effect [19]. Because wi > 1,
the weights are re-normalized such that the size of each treatment group in the pseudo-
population is equal to the size of the original treatment group.
After estimating the propensity score model, we create an unconfounded pseudo-population
by weighting each subject using wi. In this pseudo-population, let Y˜ (0) denote the total
number of events in the control group and Y˜ (1) denote the total number of events in the
treatment group, with fixed population sizes n0 and n1 respectively. We use a binomial like-
lihood Y˜ (1) | p1 ∼ Binomial(n1, p1) where p1 is the marginal probability of the event in the
treatment group. For the control group we analogously have Y˜ (0) | p0 ∼ Binomial(n0, p0).
We are interested in inference on the marginal outcome probabilities p0 and p1, which are
equal in expectation to the quantities in equation (2) and thus unconfounded. So using
Bayes’ rule and suppressing the fixed n0 and n1 their posteriors are given by:
P(p0 | Y˜ (0)) ∝ P(Y˜ (0) | p0) · P(p0) and P(p1 | Y˜ (1)) ∝ P(Y˜ (1) | p1) · P(p1). (3)
For the priors, we assume independent beta distributions p0 ∼ Beta(α00, α01) and p1 ∼
Beta(α10, α11). The hyperparameters, {α00, α01, α10, α11}, correspond to, respectively, prior
counts of no outcomes in the control group, counts of outcomes in the control group, counts
of no outcomes in the treatment group, and counts of outcomes in the treatment group.
We set {α00, α01, α10, α11} = {1, 1, 1, 1}, implying a flat prior distribution over [0,1] for p0
and p1, though informative hyperparameters could be specified if appropriate. The beta
priors are conjugate to the binomial likelihood and closed form posteriors for p0 and p1 are
obtained by augmenting the prior counts with those observed in the data. Thus for a given
propensity score pi(C) and observed data D = {Y ,X} corresponding to the n× 2 matrix
of observed binary outcome and treatment vectors, estimated posterior p0 and p1 are given
by:
p1 | D,pi(C) ∼ Beta
(
a1, b1
)
and p0 | D,pi(C) ∼ Beta
(
a0, b0
)
, where (4)
a1 = α11 + γ1
( n∑
i=1
XiYi
pˆii
)
; a0 = α00 + γ0
( n∑
i=1
(1−Xi)Yi
1− pˆii
)
;
b1 = α10 + γ1
( n∑
i=1
Xi(1− Yi)
pˆii
)
; b0 = α01 + γ0
( n∑
i=1
(1−Xi)(1− Yi)
1− pˆii
)
;
γ1 =
∑n
i=1Xi∑n
i=1Xi/pˆii
; γ0 =
∑n
i=1(1−Xi)∑n
i=1(1−Xi)/(1− pˆii)
.
with pˆii = pˆi(Ci). The parameter a1 is the prior number of subjects with events (α11) plus
the number of subjects with events in group 1 of the pseudo-population, and b1 is the prior
number of subjects having no events (α10) plus the number of subjects with no events in
the group 1 pseudo-population. Both are renormalized by γ1 so that their sum is equal to
the size of the original (unweighted) group 1 population. Similar interpretations hold for
a0, b0, and γ0 in group 0. With the specification {α00, α01, α10, α11} = {1, 1, 1, 1} the priors
add very little information.
We can draw J times from the outcome model for each of K draws from the propensity
score model. The jth draw from the estimated posterior distribution of the causal effect,
∆, using the kth draw for pˆik can be calculated as:
∆ˆjk | D, pˆik(C) = pˆjk1 − pˆjk0 . (5)
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Because (9) is conditional on a single value of pˆik(C), we can evaluate ∆jk|D, pˆik(C) over
the distribution of pi(C). [18] proposed combining the estimates using the law of total
variance to get:
E(∆ | D) = Epi{E(∆ | D,pi)} and V(∆ | D) = Epi{V(∆ | D,pi)}+ Vpi{E(∆ | D,pi)}, (6)
which resembles multiple imputation. Formula (6) demonstrates how the variance from
each model contributes to the final uncertainty: the average variance from the outcome
models enters as the first term in (6) and variance across the propensity scores enters as
the second term. With our proposed algorithm we get draws from the outcome model for
each propensity score draw, not just a variance estimate. Thus we recommend generating
the entire posterior density ∆ | D by simply concatenating across propensity score draws.
The variance can then be computed directly from these draws and uncertainty measures
like 95% confidence intervals can be calculated from their empirical quantiles.
[28] critiqued the approach of [18] for using a non-likelihood outcome model when gen-
erating the posterior variance in equation (6). Because we specify a weighted binomial
likelihood for the counts Y˜ (0) and Y˜ (1), our approach is grounded in the theoretical work
of [28], who used propensity score weights along with a Dirichlet distribution for Bayesian
bootstrapping to obtain posterior draws. However in contrast to the method of [28], our
approach takes advantage of conjugacy and has clear connections to more conventional
IPW.
In our supplementary materials, we show the equivalence between the posterior mean of
equation (5) and the IPW estimator in equation (2). We also provide further computational
details and R code for sampling from ∆ | D.
5 Simulation Studies
5.1 Handling of Propensity Score Distribution
[28] made the case that even in a Bayesian framework, propensity scores should be fixed
to their maximum likelihood estimates or posterior mean estimates rather than integrating
over the full distribution. However, doing so in high-dimensions ignores the crucial source
of uncertainty from estimating the propensity scores, which could potentially cause under
coverage and result in more type I errors. To test this, we first constructed some very
simple simulation scenarios. We let X ∼ Bernoulli{(logit−1(.5C1 + .5C2)} and Y ∼
Bernoulli
{
logit−1(X − .5C1 − .5C2)
}
where C1 and C2 were drawn from independent
standard normals with n = 100 subjects. We specified three Bayesian logistic models to
estimate the propensity scores. The first estimates the correct model, with C1 and C2 as
confounders. The second estimates an “over specified” model that includes C1, C2, and
8 additional covariates with no relation to treatment or outcome. Finally, we estimate an
“under specified” model that includes only C1, making C2 an unmeasured confounder.
The results after 4000 simulations appear in table 2.
In their original paper, [28] focused on analyzing propensity score estimators across
across different levels of confounding. They found that including variance from the propen-
sity score estimate tended to cause slight over coverage in all scenarios, while IPW and
fixed propensity score Bayesian estimators had either perfect coverage or under covered the
true parameter. We too find that integrating over the propensity score distribution leads to
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slight over coverage, making it slightly conservative. Fixing the propensity score parameter
estimates to the posterior means leads to good coverage when there are few variables, but
underestimates the variance in the over specified case and is slightly more biased. Because
we are primarily concerned with over specified models in high-dimensions, in which there
are likely to be many noisy variables, the robust coverage of the integrated method in this
setting is key. Thus these initial simulations supported integrating over the propensity score
distribution for high-dimensional analysis.
Table 2: Properties of Bayesian propensity score weighting over 4000 simulations where propensity scores
are either integrated over their posterior distribution or fixed to their posterior means. Sample size within
each simulation is n = 100. Coverage of 95% posterior intervals is reported.
Integrated PS Mean PS
Bias .0008 -.0069
Correct Variance .0102 .0086
Coverage 96.5% 94.7%
Integrated PS Mean PS
Bias .0006 -.0270
Overspecified Variance .0157 .0085
Coverage 96.6% 91.1%
Integrated PS Mean PS
Bias -.0519 -.0566
Underspecified Variance .0094 .0087
Coverage 91.9% 90.4%
5.2 More Realistic Simulations
We compare three Bayesian methods to estimate the propensity score distribution:
a logistic regression with weakly informative priors defined as Student-t3(0, 2.5) [13], a
logistic regression regularized by horseshoe priors, and BART with m = 200 trees grown
using default priors on the tree depth and end nodes (details in appendix). We altered
the horseshoe method slightly by replacing the half-Cauchy priors with half-t3(0, 1) priors,
which allow much easier fitting using Monte Carlo sampling without substantive difference
in estimates [30]. A naive estimate is computed as the unadjusted difference in means
between treatment groups. As a baseline competitor, we examine IPW as in equation (2)
with empirical sandwich standard errors. We also compare to targeted maximum likelihood
estimation (TMLE), a frequentist approach to causal inference in high-dimensional settings
[31]. TMLE used the SuperLearner ensemble method with unregularized and lasso penalized
logistic regression as cross-validated candidate models to fit outcome and propensity score
regressions. These regressions are combined to formulate a doubly-robust estimate of the
ATE [31].
We ran 500 simulations with n = 1000 and p = 100 constructed to partly resemble
our coronary stent data in terms of coefficient values and confounder distributions, while
remaining computationally tractable. To this end, 100 binary confounders were extracted
from the data, fit to the treatment variable using logistic regression, and rounded to the
nearest 10th. These estimated coefficients were then used as the true treatment coefficients
(βX) in simulated datasets. The values of βX ranged from -1.1 to 1.1 on the log-odds
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scale, with a lower quartile of -0.2 and upper quartile of 0.2, making most of the coefficients
quite small, though only 18 were exactly equal to 0. The confounders C were drawn from
independent Bernoulli distributions with probabilities equal to their empirical prevalence
in our data. As a result, many of the covariates were quite sparse. The outcome coefficients
βY were then selected to create confounding while enforcing
∑
βY = 0. The data were
simulated following: P(Xi|Ci) ∼ Bernoulli{logit−1(βX0 +
∑p
j=1 β
X
j Cij)}, yielding a marginal
treatment probability of P(Xi = 1) ≈ .7, and P(Yi|Xi,Ci) ∼ Bernoulli{logit−1(βY0 +βTrXi+∑p
j=1 β
Y
j Cij)}. We set βTr = −2, yielding an ATE over C of ∆ ≈ −0.15. An outcome
intercept of βY0 = −2 gave a relatively low event rate with P(Yi = 1) ≈ 0.1. We assessed
bias, mean squared error (MSE), confidence interval width, and realized 95% posterior
interval coverage of each method.
Weakly informative t3(0, 2.5) priors had almost perfect coverage, but the highest MSE
of any method (Table 3). The lack of regularization likely made the treatment regressions
unstable, and IPW suffered from similarly poor MSE results. The horseshoe and BART
faired better, with considerably improved MSE, tight confidence intervals, and reasonably
good coverage. BART even improved slightly over the horseshoe in terms of bias and
coverage. It’s competitive performance is remarkable because, unlike the logistic regression-
based approaches which correctly specified the model as linear, BART is completely non-
parametric.
Fixing the propensity scores to their posterior means considerably reduced variance
estimates, as evidenced by tighter confidence intervals for all methods, but led to poor
coverage as a result. Although the MSE of the t3(0, 2.5) priors improved, the MSE and
bias were actually slightly higher for the other Bayesian methods. As expected, the naive
difference in means performed very poorly. The IPW suffered from poor MSE and slightly
under-covered the true treatment effect. While the TMLE had among the best performance
with the lowest MSE, low bias, and tight confidence intervals, it under-covered the true
treatment effect considerably, indicating the inadequacy of it’s standard error estimate.
Bootstrapping TMLE would likely yield better coverage by incorporating uncertainty from
estimating the scores, but was computationally infeasible in this simulation setting.
Our simulations show the effectiveness of Bayesian propensity scores and support in-
cluding uncertainty from the propensity score distribution when fitting large treatment
models. We also demonstrated the utility of Bayesian methods for regularization and non-
parameteric regression for reducing the MSE of high-dimensional causal estimates.
6 Application: Drug Eluting vs Bare Metal Coronary Stent-
ing in Massachusetts
We revisit a comparison of the causal effect of using drug-eluting stents (DES) to bare-
metal stents (BMS) on the risks of all-cause mortality and a composite endpoint including
mortality, acute myocardial infarction, and target vessel revascularization (TVR) within 1
year after the initial procedure. Past studies using propensity score techniques have con-
sistently found a benefit to drug-eluting stents on lowering rates of 1-year mortality. In
contrast RCTs and an instrumental variables analysis report no such benefit [20] [32] [4].
However, these analyses have utilized well fewer than 100 variables for confounding adjust-
ment. An analysis using a richer confounder set may align more closely with experimental
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Table 3: Bias (estimate - true effect), mean squared error times 1000 (MSE ×103), average confidence
interval (CI) width, and coverage of 95% posterior intervals for various estimators over 500 simulations with
sample size n = 1000 and p = 100 confounders specified above. Bayesian propensity scores were implemented
with different treatment of the propensity score distribution (integrated or mean), and different modeling
choices (horseshoe priors, t3(0, 2.5), or Bayesian additive regression trees (BART)). A naive difference
in means, classic inverse probability weighting with robust standard errors (IPW), and targeted maximum
likelihood (TMLE) were also evaluated.
Treatment Model Bias MSE ×103 CI Width Coverage
Integrated Propensity Score
Logistic, t3(0, 2.5) Priors -.011 2.82 .220 95.2%
Logistic, Horseshoe Priors .016 0.93 .110 93.0%
BART, Default Regularizing Priors .011 0.84 .123 96.8%
Mean Propensity Score
Logistic, t3(0, 2.5) Priors -.001 1.59 .095 79.2%
Logistic, Horseshoe Priors .018 0.96 .092 86.0%
BART, Default Regularizing Priors .015 0.86 .093 87.2%
Other Methods
IPW -.001 1.67 .151 92.8%
TMLE .006 0.78 .075 81.4%
Naive Estimate .030 1.46 .092 73.0%
results. Although we are primarily interested in TVR, we use a composite endpoint, which
has been used in past stent trials, to avoid bias due to competing risks.
We examined n = 8718 patients from the Mass-DAC clinical registry consisting of
percutaneous coronary interventions (PCIs) performed in Massachusetts adults between
October 1, 2010 and September 30, 2011 inclusive. We merged the Mass-DAC data with
hospital billing data from the Massachusetts Center for Health Information and Analysis
(CHIA). The Mass-DAC data contributed 131 potential confounders, a mix of measures
indicating patient characteristics (e.g. age, sex), pre-existing conditions (e.g. diabetes,
heart failure), or characteristics of the procedure (e.g. treated vessel, hospital). There were
12 continuous covariates, the remainder being binary or categorical covariates. The CHIA
data included 15 free-response fields containing Present On Admission (POA) diagnoses
entered as International Classification of Diseases, 9th Version (ICD-9) codes. POA codes
describe patients at hospital arrival and therefore not impacted by treatment decisions. To
set a lower bound on sparsity we considered all diagnoses for which 10 or more patients
were coded as having the condition and converted them to dummy variables. This yielded
364 additional covariates for a total of 495 potential confounders. Henceforth we refer to
the combined dataset as Mass-DAC. We imputed a small amount of missing data, creating
one imputed dataset for simplicity. Due to the small amount of missingness substantive
inferences would be unlikely to change if we had used multiple imputed datasets.
We estimate the ATE using Bayesian propensity score weighting with treatment models
estimated from the full Mass-DAC data. Our causal parameter is defined as the average
event rate in the BMS group subtracted from the average event rate in the DES group.
We focus on analyzing two outcomes: 1-year mortality and a composite endpoint of 1-
year mortality, acute myocardial infarction (AMI), and TVR. We derived 1-year AMI from
records of in-hospital events as mandated in the Mass-DAC registry, or from any within-
12
year hospital readmission with diagnosis code 410.x1 in the CHIA data. We defined 1-year
TVR as a PCI on the same vessel or any coronary artery bypass graft (CABG) surgery
within 1 year of stent implantation. As an additional check, we include 30-day mortality
as a falsifiability endpoint. Since a true causal effect on mortality is unlikely to manifest
after 30-days, we know a significant difference on this outcome is attributable to residual
confounding.
For the first stage we estimated Bayesian models with three different specifications:
Student-t priors, horseshoe priors, and BART with 2000 trees grown using default parame-
ters. The logistic regressions were fit using Stan and convergence was assessed by inspecting
trace plots and by ensuring all within-chain relative to between-chain statistics (R-hat) were
less than 1.1 [30]. BART was fit in R using the package BayesTree, written by the orig-
inal authors [9]. We implemented an IPW estimator as in equation (2) where propensity
scores were estimated with logistic regression and the variance estimate used the empirical
sandwich method or 2000 bootstrap replicates [2]. As a final competitor, we implemented
TMLE with SuperLearner using unregularized and lasso penalized logistic regression as
candidate models, with variance estimated from the influence curve or from 1000 bootstrap
replicates [31]. We denote the sandwich variance IPW and influence curve variance TMLE
with the preface analytic, to reflect the closed-form nature of their variance estimates. We
expect the analytic methods to have tighter confidence intervals because they do not reflect
variance from the propensity score model.
We assess positivity, balance, and stability of our estimated propensity scores. We also
examine the distributions of weights and the (weighted) absolute standardized differences in
covariates between the DES and BMS groups [2]. High weights tend to result from an overfit
propensity score model and can also indicate a positivity violation, though low weights are
no guarantee of good overlap [23]. The standardized difference in covariates provides a
measure of balance, where an absolute standardized difference of less than 10% is considered
negligible [2]. For the Bayesian methods, we graphically examined the distributions of
balanced standardized differences in order to assess post-weighting covariate balance as well
as the stability of the estimates. Optimally, the 95% posterior intervals for the standardized
difference would be within (−10, 10) for all confounders, though in analogy to standard
propensity score analyses balance is acceptable if all posterior means are within (−10, 10)
[18]. Finally, we assessed the distribution of propensity score weights across subjects for
both our Bayesian and non-Bayesian methods, defined as Xi/pii+(1−Xi)/(1−pii). For the
Bayesian methods the analyzed weights correspond to each subjects posterior mean weight,
while for the frequentist methods there is only 1 weight (from the maximum likelihood
propensity score) returned for each person.
6.1 Results
All Bayesian methods converged satisfactorily according to the trace plots and R-hat statis-
tics. All TMLE bootstrap iterations fit, though about 25% of the bootstrapped IPW esti-
mates failed to converge as a result of the data sparsity and lack of regularization.
Figure 1 shows the distribution of the percent standardized differences for each of the
495 confounders for the Bayesian propensity score methods, sorted by the mean under
weakly informative t3(0, 2.5) priors. The t3(0, 2.5) priors for the logistic treatment regres-
sion coefficients show a significant portion of the standardized difference distributions for
some confounders outside of the -10% to 10% range. In contrast, the standardized difference
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distributions under horseshoe priors for the logistic treatment regression coefficients and
those using a BART treatment model were almost all entirely within an acceptable range.
Due to their heavier regularization, the posteriors under horseshoe priors and BART are
more stable. The fact that some parts of the posterior under t3(0, 2.5) priors do not suffi-
ciently balance the confounders is concerning. The t3(0, 2.5) priors had the highest average
and maximum weights of all the approaches, while horseshoe priors and BART had the
lowest. None of the methods’ weights indicated a positivity violation.
Figure 1: Mean (orange) and 95% posterior interval (blue) of standardized difference for each confounder
after balancing on each draw from the propensity score model. Each panel represents a different propensity
score model specification. The dotted lines at -10 and 10 indicate range usually taken to be acceptable. Points
are sorted by the mean standardized difference from the weakly informative t3(0, 2.5) specification.
Table 4 displays the point estimates and 95% posterior intervals for each method and
outcome. In terms of the estimated causal effect, every method sharply decreased the mag-
nitude of the naive 1-year (30-day) mortality difference from 6.9 (3.4) while also decreasing
the magnitude of the composite endpoint difference from 9.4. Even after adjustment, most
methods found a significant benefit to mortality for DES. This is particularly concerning for
30-day mortality as any differences observed that soon after implantation are almost cer-
tainly a result of residual confounding. Only bootstrapped IPW and Bayesian propensity
scores with t3(0, 2.5) priors found no significant DES benefit to 30-day mortality, though the
other methods found only a small benefit. Only the Bayesian logistic treatment model with
t3(0, 2.5) priors found no benefit to 1-year mortality. These findings may reflect residual
confounding, as past RCTs and instrumental variables analyses have repeatedly confirmed
no mortality benefit [32] [4]. However, our methods did adjust away considerably more
confounding than [20], which also used the Mass-DAC data. As expected, all methods
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found a significant DES benefit to the composite endpoint, as shown in clinical trials.
Figure 2 compares standardized posterior mean coefficient estimates for the Bayesian
logistic regression treatment model with t3(0, 2.5) priors and horseshoe priors. Sparser
binary covariates appear to the right and are shrunk significantly towards zero by the
horseshoe priors. The horseshoe priors may be shrinking the coefficients of sparse binary
covariates too aggressively, as they may be rare but important confounders. On the other
hand, imposing little regularization can be problematic as well, evidenced by our simulation
studies, the instability apparent in figure 1, and the fact that almost 500 of our 2000
bootstrapped IPW estimates failed to converge.
Figure 2: Posterior mean coefficients on log-odds scale, estimated from the Mass-DAC propensity score
model for weakly informative t3(0, 2.5) and horseshoe priors. The 12 continuous covariates appear on the far
left, and the remaining binary indicators are sorted in order of decreasing density. Thus indicators observed
in many subjects appear towards the left side of the plot and rarely observed indicators appear towards the
right. Continuous confounders were standardized before fitting for compatibility with regularization priors,
binary coefficients were standardized only for this display.
BART provided covariate balance and estimates of the risk difference comparable to
the horseshoe priors. In this example, accommodating non-linearities and interactions did
not make a large difference on the causal estimate compared to the main effects logistic
models.
7 Discussion
The methods we discussed combine the advantages of a Bayesian framework and fre-
quentist propensity scores for causal inference with many variables, where including as
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many confounders as possible will help meet the ignorability assumption. In particular,
Bayesian logistic regression using Student-t priors or horseshoe priors and BART provide
useful parametric and non-parametric options to estimating propensity score distributions
from high-dimensional data sets. Through simulations we showed that integrating over
the propensity score model can slightly reduce bias and mean squared error but signifi-
cantly improve coverage in high-dimensional settings. Because a significant portion of the
variance in a propensity score analysis stems from estimating the scores, incorporating un-
certainty from the propensity score regression was important to achieving good coverage in
our Bayesian approaches. We also found that IPW coupled with bootstrapping gave more
reasonable inferential results in our application than the empirical sandwich method, which
does not account for uncertainty in the propensity score model.
We proposed horseshoe priors and BART as techniques for variance reduction and
flexible model fitting. While these approaches dominated more conventional Student-t
priors in our simulations and looked better diagnostically in our application, they failed to
meet our falsifiability endpoint. For causal inference, we recommend weakly informative
priors for known confounders, airing on the side of reducing bias over variance, incorporating
substantive knowledge for variable selection and prior specification when available, and
using sparsity-inducing priors when there is noisy data. A Bayesian framework provides
a comprehensive and intuitive way to build models that include substantive knowledge
and regularization, as well as adaptive specifications when little is known about the data
generating process.
In our application we assessed the benefits of DES over BMS on preventing mortality
and a composite endpoint. We found that by including a rich set of almost 500 confounders
for adjustment and using Bayesian propensity scores we were able to adjust for considerably
more confounding than an earlier propensity score analysis with the same data [20]. When
used with weakly informative priors our method aligned with estimates observed in RCTs
[4].
Given that a few approaches exist for causal inference in high-dimensional data set-
tings we have several recommendations. First, although the treatment model is essentially
a nuisance parameter, accounting for the uncertainty of who receives what treatment is
important in any approach. Second, an outcome free design in which the treatment model
is separated from the outcome model is often desirable and sometimes mandated. Third,
making fewer parametric assumptions in the outcome model, for example by using a weight-
ing procedure instead of regression adjustment, is advantageous. Our approach meets these
criteria. The methods we discussed did not use any information from the outcome in setting
up the design (treatment) model, allowing the user to focus on designing a good propen-
sity score model without revealing the causal effect until balance has been achieved [26].
Such an approach is not without drawbacks, as including outcome information can aid vari-
able selection or enable doubly-robust estimation [29][33][24][7]. Nevertheless, propensity
scores remain a powerful and popular tool for causal inference and we believe that our
proposed methods provide a useful framework for comparative effectiveness research with
high-dimensional data.
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A Bayesian Propensity Score Algorithm
This section provides further detail on computing the ATE using a Bayesian outcome model
as the second step, introduced in the main paper.
In practice, we first estimate the propensity score model, simulating from the poste-
rior distribution of pi using MCMC. To draw samples from our regularized models, we
used Hamiltonian Monte Carlo implemented in Stan and analyzed using the RStan pack-
age [15][5]. BART models for the propensity score were fit using the BayesTree package
developed by the original authors and available in R [8]. A regularized logistic model gives
draws of the coefficient vector β̂k, from which we can calculate p̂ik(C) as the vector of fitted
values: p̂ik(C) = logit
−1β̂kC, where we have augmented C with a vector of 1s as the first
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column to represent the intercept. Similarly, BART outputs p̂ik(C) as fitted value draws
from the probit sum-of-trees model.
We now present two different approaches depending on whether we want to integrate
over or fix the propensity score. Throughout this section, i ∈ {1, ...N} indexes subjects,
k ∈ {1, ...K} indexes draws from the propensity score model, and j ∈ {1, ...J} indexes
draws from the outcome model conditional on the propensity score.
A.1 Fixed Propensity Score
Saarela et al (2015) fixed the propensity score to it’s posterior mean in analogy to frequentist
propensity score analyses, in which the scores are fixed to their maximum likelihood estimate
[28]. The posterior mean propensity score for each subject can simply be calculated as
E[pi(Ci)] = 1K
∑K
k=1 pik(Ci). Then conditional on the vector of mean propensity scores
E[p̂i(C)] = {E[pi(C1)],E[pi(C2)], ...E[pi(CN )]} and the observed data D = {Y ,X}, we can
sample from the closed form beta posterior distributions for p1 and p0:
p̂0 | D,E[p̂i(C)] ∼ Beta
(
a0, b0
)
p̂1 | D,E[p̂i(C)] ∼ Beta
(
a1, b1
)
a1 = α11 + γ1
( n∑
i=1
XiYi
E[pi(Ci)]
)
; b1 = α10 + γ1
( n∑
i=1
Xi(1− Yi)
E[pi(Ci)]
)
,
a0 = α00 + γ0
( n∑
i=1
(1−Xi)Yi
1− E[pi(Ci)]
)
; b0 = α01 + γ0
( n∑
i=1
(1−Xi)(1− Yi)
1− E[pi(Ci)]
)
.
γ1 =
∑n
i=1Xi∑n
i=1Xi/E[pi(Ci)]
; γ0 =
∑n
i=1(1−Xi)∑n
i=1(1−Xi)/(1− E[pi(Ci)])
.
These can easily be done in R by simulating using the function rbeta. For a single draw
p̂0j and p̂1j , we get a single draw ∆̂j from the posterior ∆̂ | D,E[p̂i(C)] as the difference:
∆̂j = p̂j1 − p̂j0
We make J such draws to get a representative sample from ∆̂ | D,E[p̂i(C)]. The poste-
rior mean causal effect is 1J
∑J
j=1 ∆̂j with variance
1
J−1
∑J
j=1(∆̂j − 1J
∑J
j=1 ∆̂j)
2. Posterior
intervals can be calculated from the empirical quantiles of {∆̂1, ∆̂2, ...∆̂J}.
A.2 Integrating over Propensity Score Distribution
Kaplan and Chen (2012) and Graham (2016) proposed integrating over the propensity
score distribution to propagate uncertainty [18][10]. To integrate over the propensity score
distribution we generate draws from the outcome model for each draw from the propensity
score model, and base posterior inferences on the resulting J ×K total draws.
For k ∈ {1, 2, ...K} we condition on the kth propensity score draw p̂ik(C) and the data
D to get draws from the posterior pk1 and pk0
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p̂k0 | D, p̂ik(C) ∼ Beta
(
ak0, bk0
)
p̂k1 | D, p̂ik(C) ∼ Beta
(
ak1, bk1
)
ak1 = α11 + γ1
( n∑
i=1
XiYi
pik(Ci)
)
; bk1 = α10 + γ1
( n∑
i=1
Xi(1− Yi)
pik(Ci)
)
,
ak0 = α00 + γ0
( n∑
i=1
(1−Xi)Yi
1− pik(Ci)
)
; bk0 = α01 + γ0
( n∑
i=1
(1−Xi)(1− Yi)
1− pik(Ci)
)
.
γk1 =
∑n
i=1Xi∑n
i=1Xi/pik(Ci)
; γk0 =
∑n
i=1(1−Xi)∑n
i=1(1−Xi)/(1− pik(Ci))
.
For a single draw p̂0kj and p̂1kj , we get a single draw ∆̂jk from the posterior ∆̂ | D, p̂ik(C)
as the difference:
∆̂jk = p̂1kj − p̂0kj
We make J such draws to get a representative sample from ∆̂ | D, p̂ik(C).
To get the posterior mean and variance of the ATE across both propensity score draws
and outcome draws we compute:
E(∆̂ | D) = 1
K
1
J
K∑
k=1
J∑
j=1
∆̂jk (7)
V(∆̂ | D) = 1
K
K∑
k=1
{
1
J − 1
J∑
j=1
(
∆̂jk − 1
J
J∑
j=1
∆̂jk
)2}
+
1
K − 1
K∑
k=1
{
1
J
J∑
j=1
∆̂jk − E(∆̂ | D)
}2 (8)
(7) averages over all draws. (8) is simply the law of total variance as commonly used for
multiple imputation and adds the “within” and “between” variance for each propensity
score draw. Note that the first term in (8) gives the average variance within outcome draws
conditional on the propensity score, and the second term in (8) gives the variance of the
average estimate conditional on the propensity score.
However we recommend not using (8) to get approximate credible intervals, as we
can just take the empirical quantiles of the J × K draws ∆̂jk after concatenating across
propensity score draws into the vector {∆11, ...∆J1,∆12, ...,∆1K , ...∆JK}. For example, the
2.5th and 97.5th percentiles provide the ends of the 95% credible interval for ∆ | D. Any
other posterior summaries (e.g. P(∆ > 0)) can be computed in this way as well.
B Link to Frequentist Inverse Probability Weighting
Here we let p̂i = p̂i(C) and pi(Ci) = pii for simplicity, we assume that p̂i is correctly
estimated, and we ignore its uncertainty. Our goal is just to show that our estimator,
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∆̂ | D, p̂i = p̂1 − p̂0, (9)
is equal (or arbitrarily close) in expectation to ∆̂IPW2 from Lunceford and Davidian
(2004), i.e. E(∆̂ | D, p̂i) = ∆̂IPW2, which the authors showed is consistent under the
assumption that pi is properly specified [19]. In fact we only need to show that E(p1) =
µ̂1 =
(∑n
i=1
Xi
pii
)−1∑n
i=1
XiYi
pii
and E(p0) = µ̂0 =
(∑n
i=1
1−Xi
1−pii
)−1∑n
i=1
(1−Xi)Yi
1−pii due to the
linearity of expectations. Note that if Z ∼ Beta(a, b), then E(Z) = aa+b . Assuming improper
priors α11 = α10 = 0 for p1 we have:
E(p̂1) =
γ1
(∑n
i=1
XiYi
pii
)
γ1
(∑n
i=1
XiYi
pii
)
+ γ1
(∑n
i=1
Xi(1−Yi)
pii
) (10)
=
γ1
γ1
(∑n
i=1
XiYi
pii
)(∑n
i=1
XiYi
pii
)
+
(∑n
i=1
Xi(1−Yi)
pii
) (11)
=
(∑n
i=1
XiYi
pii
)(∑n
i=1
XiYi
pii
)
+
(∑n
i=1
Xi(1−Yi)
pii
) (12)
=
(∑n
i=1
XiYi
pii
)(∑n
i=1
XiYi+Xi(1−Yi)
pii
) (13)
=
(∑n
i=1
XiYi
pii
)(∑n
i=1
Xi
pii
) (14)
= µ̂1 (15)
The arithmetic for E(p̂0) = µ̂0 is nearly identical and we omit the details. Thus E(∆̂ |
D, p̂i) = E(p̂1)− E(p̂0) = µ̂1 − µ̂0 = ∆̂IPW2, which is consistent. With proper priors E(p̂1)
is not exactly equal to µ̂1, but converges to it as n gets large and the data overwhelm the
prior. For flat priors α = 1 or Jeffrey’s priors α = 12 , the prior plays very little role for even
moderate n.
The variance of the difference of two Betas does not have a simple closed form and
we use MCMC for inference. We found good coverage of 95% posterior intervals in our
simulations, though other methods like TMLE may be more efficient.
C BART Details
BART is a nonparametric modeling technique that translates decision tree-based ensemble
methods, such as random forests, to a Bayesian framework. Such approaches are especially
desirable when the form of the model is unknown, as nonlinearities and interactions in
regression problems are accommodated. Chipman et al provide a thorough introduction
to the method, and the version of BART we use here is identical to the authors’ original
BART-probit formulation for binary regression [9]. Briefly, let T denote a classification tree
with it’s associated binary decision rules, M = {µ1, µ2, ...µL} a set of parameter values for
each of L terminal nodes, R the total number of trees, and g(Ci|T,M) a function assigning
value µl to Ci (i.e. a single tree model). Then the BART-probit sum-of-trees model for a
binary treatment is given by:
23
P(Xi = 1|Ci) = Φ
{ R∑
r=1
g(Ci|Tr,Mr)
}
, (16)
where Φ is the CDF of the standard normal. Regularizing priors are then placed over Tr
to limit the “depth” of individual trees and over Mr to shrink µlr towards zero, controlling
the effect of individual terminal nodes. The original authors provide default specifications
for these parameters, which we use throughout this paper [9].
Specifically, independence is assumed between trees Tr given nodes Mr, and between
the terminal nodes µlr given Tr. Thus:
P(T1,M1, T2,M2, ..., TR,MR) =
R∏
r=1
P(Tr,Mr) =
R∏
r=1
P(Mr|Tr)P(Tr) (17)
P(Mr|Tr) =
L∏
l=1
P(µlr|Tr) (18)
This greatly simplifies prior specification as we can set a prior relatively intuitively for
the individual pieces P(Tr) and P(µlr|Tr).
P(Tr) is specified in 3 parts: the probability that each node is non-terminal (a leaf),
the distribution over splitting variables, and the distribution over possible splitting values.
The latter two are simply set to be uniform over all potential variables and splitting values.
The prior on node depth d is more consequential and is given by:
a(1 + d)−b, where a ∈ (0, 1), b ∈ [0,∞) (19)
a and b are essentially regularizing parameters that control how deep individual trees
are allowed to grow. Shallow trees are less flexible and tend towards an additive model
(no interactions) at the limit of 1 split. The authors experimented with various settings to
control the depth and recommend the choices b = 2 and a = .95 as good defaults, which
put most prior mass on trees of around depth 2 or 3 [9]. We used only these settings in our
simulated and applied analyses, and did not “tune” these parameters.
P(µlr|Tr) is specified as a normal distribution N (0, σµ) with σµ = 3/c
√
R. This shrinks
the parameter estimates towards 0 on the probit scale (i.e. 0.5 on the probability scale).
The idea is to put high prior probability that P(Xi = 1|Ci) is in the interval [Φ(−3),Φ(3)] =
[.001, .999] and the tuning parameter c is chosen to achieve this. The authors recommend
c ∈ [1, 3] and suggest c = 2 as a good default, which is the specification that we used
throughout this article [9].
As a final specification, the authors recommend fixing R, the size of the forest grown
[9]. The reason for fixing this parameter is to greatly reduce the computational burden that
would be incurred by treating R as an unknown parameter.
Gibbs sampling can be used to obtain posterior draws from a BART-probit model. We
use the R package BayesTree to fit BART-probit and extract a propensity score distribution
[8].
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Table 5: Bias (estimate - true effect), confidence interval width, and coverage for various estimators over
500 simulations with sparse coefficients as described above and sample size n = 1000.
Bias MSE ×103 CI Width Coverage
Naive Estimate .013 0.95 .101 89.0%
Integrated Propensity Score
Logistic t3(0, 2.5) Priors -.009 3.10 .234 95.6%
Logistic Horseshoe Priors .002 0.94 .126 95.2%
BART-Probit .001 1.01 .203 98.8%
Mean Propensity Score
Logistic t3(0, 2.5) Priors -.002 1.74 .100 79.8%
Logistic Horseshoe Priors .004 0.86 .100 91.6%
BART-Probit .005 0.71 .100 93.6%
Frequentist Methods
Inverse Probability Weighting -.003 1.62 .164 96.8%
TMLE .000 0.63 .070 84.0%
D Sparse Simulations
We repeat the “realistic” simulation study done in the main paper, but with sparse under-
lying coefficients. To achieve this, we set 90 of the 100 propensity score coefficients exactly
equal to zero. The remaining coefficients had magnitudes between .8 and 1.1, making them
relatively strong predictors of treatment and important confounders. Otherwise the model
was specified in exactly the same way as in the main paper.
Again, all of our methods achieved a bias reduction compared to the naive estimate. The
variance of the t3(0, 2.5) was large and resulted in terrible mean squared error (MSE) and
wide confidence intervals that overcovered the true effect. Along with IPW and integrated
BART, the MSE was actually worse than an unadjusted estimate, though coverage was
improved.
Integrated Bayesian propensity scores using a logistic treatment model with horseshoe
priors performed the best, with tight confidence intervals, low MSE, and coverage very
near 95%. BART had wider confidence intervals and also slightly overcovered the causal
effect. All of Bayesian methods had better coverage when integrating over the propensity
score, though mean squared error was better when the propensity score was fixed due to
the decrease in variance. TMLE is also unbiased and very efficient with the lowest MSE of
any method, but suffered from significant undercoverage.
E Complete Mass-DAC Covariates
The full list of covariates from the Mass-DAC clinical registry appears in table 6. We
include prevalences or mean and standard deviation overall and in each treatment group.
For the sake of space and to conform to privacy requirements, we summarize the site and
artery segment variables for which there are 25 and 31 categories, respectively.
25
Table 6: Prevalence or mean (SD) of variables in Mass-DAC registry. Columns denote prevalence or
mean (SD) overall and conditional on treatment received. All potential confounders are pre-treatment. Cells
representing data on fewer than 10 patients are suppressed in accordance with privacy guidelines. TVR =
target vessel revascularization; AMI = acute myocardial infarction; HMO = health maintenance organiza-
tion; CAD = coronary artery disease; CVD = cardiovascular disease; PAD = peripheral artery disease;
CABG = coronary artery bypass graft; STEMI = ST-elevated myocardial infarction; LVSD = left ventric-
ular systolic dysfunction; NYHA = New York heart association; LAD = left anterior descending (artery);
RCA = right coronary artery.
Registry Outcomes Overall (n = 8718) BMS (n = 3081) DES (n = 5637)
1 Year Mortality-AMI-TVR Composite 17.96 24.02 14.65
1 Year Mortality 5.75 10.19 3.32
30 Day Mortality 2.01 4.19 0.82
Registry Confounders
Male 69.39 68.16 70.05
Mean Age (SD) 64.66 (12.5) 66.37 (11.7) 63.72 (13.5)
Mean Height (SD) 170.67 (10.5) 170.41 (10.6) 170.81 (10.4)
Mean Weight (SD) 86.48 (20.3) 84.89 (19.9) 87.34 (20.8)
Race
Caucasian 91.26 90.72 91.56
Black 3.79 4.87 3.19
Asian 2.31 2.43 2.24
Native American < 0.1 < 0.3 < 0.2
Native Pacific < 0.1 < 0.3 < 0.2
Hispanic or Latino 4.55 4.8 4.42
Payor
Government 51.57 59.17 47.42
None 2.56 4.12 1.7
Non-US < 0.1 < 0.3 < 0.2
Private Commercial or HMO 45.82 36.68 50.82
Smoker 74.68 70.85 76.78
Hypertension 78.3 76.6 79.23
Dyslipidemia 81.82 77.96 83.93
Diabetes 32.16 30.38 33.14
Family History CAD 28.96 24.08 31.63
Chronic Lung Disease 14.21 16.42 13
Current Dialysis 1.82 2.21 1.61
Prior CVD 10.23 11.33 9.63
Prior PAD 11.96 12.76 11.53
Prior Myocardial Infarction 26.67 25.84 27.12
Prior Heart Failure 10.61 12.46 9.6
Prior Valve Surgery 1.56 2.34 1.14
Prior PCI 27.56 19.77 31.83
Prior CABG 12.3 11.46 12.76
Prior Cardiogenic Shock 1.9 3.89 0.82
Prior Cardiac Arrest 2.29 4.15 1.28
CAD Presentation
No Angina 5.32 5.78 5.07
Symptom Unlikely to be Ischemic 1.00 1.17 0.90
Stable Angina 11.88 5.81 15.2
Unstable Angina 30.19 23.4 33.9
Non-STEMI 27.23 28.17 26.72
STEMI 24.37 35.67 18.2
Thrombolytic Therapy 0.8 1.23 0.57
Cardiomyopathy or LVSD 9.36 11.1 8.41
Anginal Canadian Classification
0 9.64 11.65 8.53
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I 2.4 1.59 2.84
II 12.2 7.66 14.69
III 28.83 24.15 31.38
IV 46.94 54.95 42.56
Anti-Anginal Medications
Beta Blockers 57.79 54.56 59.55
Calcium Channel Blockers 11.44 11.39 11.46
Long Acting Nitrates 11.49 9.41 12.63
Ranolazine 0.62 0.45 0.71
Other Agent 1.4 1.01 1.61
NYHA Class
0 87.57 83.51 89.78
I 0.91 0.78 0.98
II 3.06 3.67 2.73
III 4.16 5.39 3.49
IV 4.3 6.65 3.02
Compassionate Use 0.91 2.01 0.3
Cardiogenic Shock 1.85 3.8 0.78
Mechanical Ventricular Support 0.58 1.14 0.28
Ejection Fraction < 30% 2.88 3.7 2.43
Coronary Anatomy
Left Dominant 8.30 8.08 8.42
Right Dominant 86.19 85.88 86.36
Left Dominant 5.51 6.04 5.22
Left Main Disease 5.93 6.52 5.61
Mean Left Main Stenosis (SD) 7.98 (19.8) 8.74(19.3) 7.57(20.7)
Mean Proximal LAD Stenosis (SD) 36 (39.7) 35.1(39.7) 36.5(39.5)
Mean Mid-Distal LAD Stenosis (SD) 48.2 (39.7) 47.64(39.7) 48.51(39.6)
Mean Circumflex Stenosis (SD) 47.95 (40.8) 47.94(40.7) 47.96(40.8)
Mean RCA Stenosis (SD) 60.66 (39.9) 65.25(40) 58.15(39.2)
Status
Urgent 52.49 48.78 54.51
Emergent 26.69 38.30 20.35
Other 20.82 12.92 25.14
PCI Indication
Immediate PCI for STEMI 21.80 31.39 16.55
STEMI (Unstable, > 12 hours) 1.67 2.66 1.14
STEMI (Stable, > 12 hours) 0.57 0.94 0.37
STEMI (Stable, thrombolytics) 0.44 0.58 0.35
STEMI (Rescue, failed thrombolytics) 0.46 0.75 0.3
High risk Non-STEMI 48.99 45.86 50.7
Staged 0.86 0.45 1.08
Other 25.21 17.36 29.5
Thrombectomies Used 0.12 (0.3) 0.16(0.3) 0.09(0.4)
Lesions Treated 1.3 (0.6) 1.24 (0.6) 1.33 (0.5)
Lesion Length 18.08 (10) 17 (10.4) 18.68 (9.3)
Chronic Total Occlusion 1.73 1.3 1.97
In-stent Restenosis 6.96 2.34 9.49
Total Stents Used 1.46 (0.8) 1.41 (0.8) 1.5 (0.8)
Sites (25 Total)
Min Volume 47 12 14
Mean Volume (SD) 349 (269) 123 (99) 225 (187)
Max Volume 896 352 605
Coronary Artery Segments (31 Total)
Min Volume 2 1 1
Mean Volume (SD) 375 (534) 126 (183) 249 (358)
Max Volume 1903 611 1335
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Table 7: Prevalence of top 30 most frequently recorded ICD-9 diagnosis codes in CHIA
billing data, overall and by treatment group. Codes are grouped into 3 digit broad categories
for simplicity of presentation while models use more-granular 5 digit codes.
ICD-9 Code Overall BMS DES
414: Other forms of chronic ischemic heart disease 86.24 88.28 85.12
272: Disorders of lipoid metabolism 69.47 62.67 73.18
401: Essential hypertension 62.20 57.25 64.91
410: Acute myocardial infarction 53.99 66.44 47.19
250: Diabetes mellitus 30.36 27.98 31.67
305: Nondependent abuse of drugs 21.51 25.45 19.35
411: Other acute and subacute form of ischemic heart disease 19.65 15.74 21.78
427: Cardiac dysrhythmias 17.13 24.41 13.15
530: Diseases of esophagus 16.87 15.97 17.37
428: Heart failure 15.46 20.12 12.91
278: Obesity and other hyperalimentation 12.03 11.13 12.52
585: Chronic renal failure 9.77 11.33 8.92
403: Hypertensive renal disease 8.99 10.52 8.16
413: Angina pectoris 7.90 4.35 9.85
244: Acquired hypothyroidism 7.26 7.27 7.26
496: Chronic airways obstruction, not elsewhere classified 7.25 9.12 6.23
300: Neurotic disorders 6.61 6.07 6.90
424: Other diseases of endocardium 6.06 8.34 4.81
443: Other peripheral vascular disease 5.38 5.55 5.29
285: Other and unspecified anemias 5.23 7.59 3.94
426: Conduction disorders 4.90 6.78 3.87
996: Complications peculiar to certain specified procedures 4.87 2.79 6.01
493: Asthma 4.84 5.42 4.52
600: Hyperplasia of prostate 4.82 5.52 4.43
327: Organic sleep disorders 4.76 4.06 5.14
311: Depressive disorder, not elsewhere classified 4.67 5.00 4.49
276: Disorders of fluid, electrolyte, and acid-base balance 4.40 6.17 3.44
715: Osteoarthrosis and allied disorders 3.46 3.51 3.44
724: Other and unspecified disorders of back 3.30 3.64 3.12
274: Gout 3.27 3.34 3.23
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